Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Metastases to brain)
20,659 results
  • Pseudoprogression of Melanoma Brain Metastases. [Review]
  • COCurr Oncol Rep 2018 Nov 09; 20(11):91
  • Simard JL, Smith M, Chandra S
  • Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in wh...
  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. [Journal Article]
  • LOLancet Oncol 2018 Nov 06
  • Solomon BJ, Besse B, … Shaw AT
  • CONCLUSIONS: Consistent with its broad ALK mutational coverage and CNS penetration, lorlatinib showed substantial overall and intracranial activity both in treatment-naive patients with ALK-positive non-small-cell lung cancer, and in those who had progressed on crizotinib, second-generation ALK tyrosine kinase inhibitors, or after up to three previous ALK tyrosine kinase inhibitors. Thus, lorlatinib could represent an effective treatment option for patients with ALK-positive non-small-cell lung cancer in first-line or subsequent therapy.
  • Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. [Journal Article]
  • JCJ Clin Oncol 2018 Nov 08; :JCO1800204
  • Kluger HM, Chiang V, … Jilaveanu LB
  • CONCLUSIONS: Pembrolizumab is active in melanoma brain metastases with acceptable toxicity and durable responses. Multidisciplinary care is required to optimally manage patients with brain metastases, including consideration of radiation to large or symptomatic lesions, which were excluded in this trial. Two-year survival was similar to patients without brain metastasis treated with anti-programmed cell death 1 agents. Concordant brain and extracerebral responses support use of pembrolizumab to treat small, asymptomatic brain metastases.
New Search Next